Q: What is the primary function of a Person-in-Plant (PIP) during the tech transfer of an allogeneic CAR-NK therapy to a UK facility?
A PIP serves as the direct scientific liaison embedded within the receiving manufacturing facility. Their function is to ensure the nuanced, unwritten operational details of the CAR-NK manufacturing process are transferred with high fidelity. This includes overseeing key process parameters, troubleshooting cell culture deviations in real-time, and ensuring the new team’s execution aligns with the validated process, which is important for MHRA submissions and maintaining GxP compliance.
Q: How does PIP support help de-risk the scale-up of complex cell-based next-generation therapies?
Allogeneic platforms like CAR-NK cells have unique biological sensitivities that are not always captured in standard batch records. PIP support de-risks scale-up by providing on-the-ground expertise to interpret process data, manage unexpected biological variability, and make informed decisions that prevent batch failures. This hands-on oversight ensures process consistency, which is fundamental for generating the robust data required for an Investigational Medicinal Product Dossier (IMPD).
Q: Can embedded PIP support accelerate the typical 18-24 month IND timeline for an ATMP?
Yes, by minimizing costly errors and delays during the manufacturing transfer. A failed transfer or inconsistent batch production can set a program back by months. An experienced PIP identifies and resolves potential process deviations before they lead to batch loss or inconclusive data, thereby preserving momentum and helping to maintain accelerated timelines toward clinical trials.
On-Site Expertise for Allogeneic CAR-NK Technology Transfer
Proven Intelligence in Complex Cell Therapy Manufacturing.
The successful technology transfer of an allogeneic CAR-NK cell therapy process is a significant operational hurdle. Standard documentation and remote meetings often fail to capture the procedural nuances required to consistently manufacture a living therapeutic product. Our Person-in-Plant (PIP) support model embeds our scientific experts directly into your designated UK or EU manufacturing facility to ensure an efficient and high-fidelity process transfer.
This on-site presence bridges the gap between process development and GxP production. Our team brings a deep history of navigating complex biological manufacturing, reflected in the 100% successful IND rate achieved by our core scientific leadership since 2019, prior to the formal launch of Franklin Biolabs in 2024.
Mitigating Risk in ATMP Manufacturing
Allogeneic CAR-NK therapies present distinct manufacturing challenges, from donor cell variability to cryopreservation logistics. Successful transfer of a living therapeutic requires an intuitive understanding of the process that standard documentation cannot fully convey.
Key areas addressed by our PIP support include:
-
Process Parameter Integrity: Direct oversight of fundamental steps like cell selection, activation, transduction with lentiviral vectors, and expansion to ensure they are replicated precisely.
-
Aseptic Technique & Contamination Control: Reinforcing best practices for handling sensitive cell cultures within the cleanroom environment of your chosen facility.
-
Real-Time Troubleshooting: Immediate intervention to address unexpected deviations in cell growth, viability, or phenotype, preventing potential batch failures.
-
Regulatory Alignment: Ensuring all on-site activities, documentation, and operator training are consistent with MHRA requirements for ATMPs.
Our methodology is built on foundational principles from the wider field of advanced therapeutics. Experience in vectorology, such as understanding vector-tissue specificity (PMID: 22937069) and developing strategies to manage host immune responses (PMID: 37833563), provides a framework for proactive biological risk mitigation. We apply this same strategic foresight to the manufacturing floor, anticipating and addressing the biological complexities of CAR-NK cells.
The Franklin Biolabs operational footprint, which includes over 100,000 sq ft of specialized laboratory and preclinical housing space, provides the foundational expertise for this level of support.
This infrastructure, combined with our strategic collaboration with leading industry partners, informs our understanding of scalable GxP operations. For a comprehensive overview of our manufacturing and analytical capabilities, see our core Vector | CMC | Analytics Services offerings.
Our PIPs become a temporary extension of your team, dedicated to one objective: making your process work successfully, on time, in its new environment.
